By Alex Gavrish, Etalon Investment Research; author of "Wall Street Back To Basics" The main beneficiary of a recent acquisition of Idenix Pharmaceuticals Inc ( IDIX) by Merck & Co., Inc. ( MRK) is Baupost Group, an investment management firm managed by Seth Klarman, a famous value investor. Baupost Group owns a large 35% stake in the company and stands to profit handsomely once the deal completes. While Klarman’s firm was quite a long term shareholder, another, smaller investor had caught our attention. Sarissa Capital, a recently launched activist hedge fund focused on healthcare investments. The fund owned 5.05 milliom shares, valued at $36.5 million based on Idenix’s market price before deal announcement. The fund just started, in 2013, to make investments and one of its main portfolio holding, as of March 31st, 2014, was Idenix. As of March 31st, 2013, position represented 11% out of a total $290 million portfolio. We decided to dig deeper and review the fund’s other holdings.